MIV Preliminary Nine-Month Human Data Affirms Excellent Safety and Efficacy of VESTAsync(TM)...

MIV Preliminary Nine-Month Human Data Affirms Excellent Safety and Efficacy of VESTAsync(TM) Polymer-Free Drug-Eluting Stent

Preliminary Results Presented at the Annual Meeting of the
American College of Cardiology Conference Call to be Held Wednesday
April 2nd, 2008 at 11:00 a.m. ET
ATLANTA--(Business Wire)--
MIV Therapeutics, Inc. (OTCBB:MIVT) (Frankfurt:MIV), a leading
developer of next-generation coatings and advanced drug-delivery
systems for cardiovascular stents and other implantable medical
devices, announced that nine month results from the first-in-man (FIM)
MIVT Pilot Trial of its VESTAsync(TM) drug-eluting stent suggest that
the stent has the potential for superior safety and equivalent
efficacy when compared to currently available drug-eluting stents.
Jose Costa, M.D. of Institute Dante Pazzanese of Cardiology in Sao
Paulo, Brazil discussed the preliminary data in a moderated poster
presentation yesterday at the 57th Annual Scientific Sessions of the
American College of Cardiology in Chicago. The presentation titled,
"Preliminary Results of the Hydroxyapatite Non-Polymer-Based
Sirolimus-Eluting Stent for the Treatment of Single de novo Coronary
Lesions: A First-in-Human Analysis of a Third-Generation Drug-Eluting
Stent System" concluded that the VESTAsync(TM) polymer-free nanoscale
microporous hydroxyapatite stent demonstrates excellent efficacy and
safety.

Dr. Costa presented nine month follow up intravascular ultrasound
(IVUS) data for 11 patients who demonstrated a volumetric obstruction
of 3.8% (+/- 2.3%) versus 2.8% (+/- 2.2%) at four months. Quantitative
coronary angiography (QCA) of 12 patients at nine months found a
late-lumen loss of 0.37mm (+/- 0.24) versus 0.31mm (+/- 0.26) at four
months. The study concluded that there was no significant difference
between the four and nine month results and that the observed
degradation was uniform across all patients with no outliers. No late
acquired incomplete stent apposition, stent thrombosis or major
adverse coronary events were reported.

Dr. Costa commented, "The preliminary nine month data of the MIVT
Pilot Trial are very encouraging, and reaffirm our positive findings
at four months. The data compare favorably with FIM data of
drug-eluting stents available in the United States and abroad, but
what is more remarkable is these results were obtained with 60% less
drug delivered from an ultra-thin 0.6 micron coating that is entirely
polymer-free."

Dr. Mark Landy, MIVT President and Chief Executive Officer
remarked, "We are very excited with the data generated from the MIVT
Pilot Trial. Not only do the data demonstrate that our VESTAsync(TM)
polymer-free drug-eluting stent is safe and effective, but we believe
that it suggests the potential to rejuvenate the worldwide
drug-eluting stent market and increase stent usage. We are looking
forward to conducting a larger trial in the coming months to further
support our belief that the VESTAsync(TM) has the potential to deliver
drug-eluting stent efficacy with bare metal stent safety, and
short-term anticoagulant therapy. We expect to begin this trial in the
second quarter of this year and look forward to providing updates as
we move ahead."

Conference Call and Webcast Information

MIV will hold a conference call and webcast on Wednesday, April 2,
at 11:00 a.m. Eastern time to discuss this announcement and to answer
questions. The speaker on the call will be Dr. Mark Landy, MIV's
president and chief executive officer. The webcast will be accessible
through the Investor Relations section of MIV's website at
www.mivtherapeutics.com, and will be archived on the website for
future on-demand replay.

Alternatively, the live call can be accessed by dialing (866) 844
- 2998 from the U.S. and Canada or (706) 634-9275 for international
callers. A telephone replay will be available from noon Eastern time
on April 2, 2008 through 11:59 p.m. Eastern Time on April 9, 2008 by
dialing (800) 642-1687 (domestic) or (706) 645-9291 (international)
and entering conference ID number 41676644.

About MIV Therapeutics

MIV Therapeutics is developing a next-generation line of advanced
biocompatible coatings for passive and drug-eluting applications on
cardiovascular stents, as well as for a broad range of other
implantable medical devices. The Company's ultra-thin coating
formulation is designed to protect surrounding tissue from potentially
harmful interactions with bare metallic stents. This coating platform
is derived from hydroxyapatite (HAp), an organic material that has
demonstrated excellent in vivo safety and biocompatibility.
Hydroxyapatite is a porous material that makes up the bone mineral and
matrix of teeth, and is widely used today as a bone substitute
material and for coatings on implantable fixation devices in
orthopedic, dental and other applications. The Company's novel
polymer-free drug-eluting technologies based on HAp could also provide
an attractive alternative to current polymer-based drug-eluting
coatings on the stent market, which have been associated with
undesirable effects. The Company's drug-eluting coatings are
additionally designed to suit a broad range of implantable medical
devices that could benefit from highly customizable drug release
profiles. MIV Therapeutics has a Collaborative Research Agreement with
the University of British Columbia and has received a government grant
for its research program on the "Development of Novel Drug Eluting
Composite Coatings for Cardiovascular Stents," under the National
Research Council-Industrial Research Assistance Program. Under this
sponsorship, the Company is expected to complete its drug-eluting
research and development program and to reach product
commercialization. MIV's intellectual property portfolio includes
patents held by the University of British Columbia and exclusively
licensed to MIV. Key patent applications filed simultaneously in
various countries around the world further protect the commercial
exclusivity of MIV's inventions in the global marketplace. For more
information, please visit www.mivtherapeutics.com.

Forward-Looking Statements

Except for the historical information contained herein, the
matters discussed in this press release are forward-looking
statements. All statements that discuss expectations and projections
with respect to future matters including, without limitation,
statements relating to the safety and efficacy of the Company's
product and the ability of the Company's product to rejuvenate the
stent market are forward-looking statements. Such statements are
indicated by words or phrases such as "proposed," "expected,"
"believe," "will," "breakthrough," "significant," "indicated," "feel,"
"revolutionary," "should," "ideal," "extremely" and "excited." These
statements are made under "Safe Harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those described in forward-looking statements and are
subject to risks and uncertainties including, without limitation,
market acceptance of the Company's product, the ability of the Company
to raise sufficient funding and to continue to develop its various
business interests as presently contemplated, and other factors
identified in the Company's filings with the Securities and Exchange
Commission including, without limitation, the Company's annual report
on Form 10-K for the year ended May 31, 2007 and Forms 10-Q. The
Company expressly disclaims any obligation to update publicly or
otherwise revise these statements, whether as a result of new
information, future events or otherwise, except to the extent required
by law.

MIV Therapeutics, Inc.
Investors:
Anthony L. Huston, 604-301-9545 ext. 14
Director of Investor Relations
ahuston@mivtherapeutics.com
investor@mivtherapeutics.com
or
Lippert/Heilshorn & Associates, Inc.
Investors:
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Schwartz Communications
Media:
Michele Fox or Cassie Wallace, 781-684-0770
miv@schwartz-pr.com

Copyright Business Wire 2008